Ricerca
3 risultati per «humanized healthcare»
La profilassi dell’infezione da virus respiratorio sinciziale: dal palivizumab al nirsevimab
Servadio M, Belleudi V, Marchetti F, Addis A. — pp. 632-639
… Dis 2018;18(10):e295-e311. doi: 10.1016/S1473-3099(19)30002-7. 18. [No authors listed]. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IM-pact-RSV Study Group. Pediatrics …
Efficacia di nirsevimab nella prevenzione del VRS: sfide e prospettive di equità
Marchetti F, Cocchi E. — pp. 619-620
… 13. Wildenbeest JG, Bont L, Cianci D, et al BRICE Study Group. Impact of RSV hospitalization on healthcare costs, caregivers' productivity loss, and quality of life in children ≤ 2 years old in five European countries. Eur J Pediatr 2025;184(11):716. doi: 10.1007/s00431-025-06460-7. …